Lund, Sweden, 16:00 CET, November 12 2019BONESUPPORT™ an emerging leader in orthobiologics for the management of bone injuries, announces changes in its leadership team that will take place November 18, 2019.
Fergus MacLeod starts in the position as the company’s General Manager & Executive Vice President Commercial Operations EUROW. Fergus MacLeod has more than 20 years of experience from international sales leadership positions within the Orthobiologics and Medical Devices sectors at companies like Johnson Matthey, RTI Surgical and Stryker.
“Fergus MacLeod will be an important addition to the BONESUPPORT leadership team. His experience in commercialising technologies as well as building and leading high performing teams will be of value for our intensified commercial activities in several markets”, says Emil Billbäck, BONESUPPORT’s CEO.
BONESUPPORT™ (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2021. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
+46 (0) 708 76 87 87